Alphatec Holdings, Inc. (ATEC) is a medical technology company focused on revolutionizing spine surgery. The company designs, develops, and advances technology to improve surgical treatment of spinal disorders. ATEC sells spinal surgery implants and medical imaging equipment, aiming to enhance surgical outcomes and expand its market presence.
- Spinal Surgery Implants - Offers pedicle screws, complementary implants, interbody devices, plates, and tissue-based materials to support spinal surgeries.
- Medical Imaging Equipment - Provides EOS full-body and weight-bearing x-ray imaging devices and related services to assist in surgical planning and execution.
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Patrick S. Miles ExecutiveBoard | Chairman and Chief Executive Officer | Patrick S. Miles has been the CEO of ATEC since March 2018 and previously served as Executive Chairman from October 2017 to March 2018. | View Report → | |
Ali Shorooghi Executive | Senior Vice President, Marketing | Ali Shorooghi is Senior Vice President, Marketing at ATEC since November 2022. He previously served as Vice President, Marketing (June 2020 to November 2022) and Senior Director, Marketing (December 2017 to June 2020) at ATEC. | ||
Craig E. Hunsaker Executive | Executive Vice President, People & Culture | Craig E. Hunsaker serves as Executive Vice President, People & Culture at ATEC since September 2016 and also leads as General Manager of EOS imaging S.A.S since September 2023. He previously served as ATEC's General Counsel from March 2017 to July 2023. | ||
David P. Sponsel Executive | Executive Vice President, Sales | David P. Sponsel has served as Executive Vice President, Sales at ATEC since April 2019, previously serving as Area Vice President, Sales, South from May 2018 to April 2019. | ||
J. Todd Koning Executive | Executive Vice President and Chief Financial Officer | J. Todd Koning has been the Executive Vice President and Chief Financial Officer of ATEC since April 2021, and he has extensive experience in previous financial leadership roles at Masimo Corporation, NuVasive, Inc., Ellipse Technologies, Inc., Boston Scientific, and Guidant Corporation. | ||
Joseph Walland Executive | Senior Vice President, Imaging Solutions | Joseph Walland has served as Senior Vice President, Imaging Solutions at ATEC since January 2022. He previously held the role of Vice President, Sales Channel Development from December 2020 to January 2022 and was the CEO at Medicrea until November 2020. | ||
Scott Lish Executive | Chief Operating Officer | Scott Lish is the Chief Operating Officer at ATEC since January 2024. Previously, he served as Senior Vice President, Research and Development from October 2020 to January 2024 and as Vice President, Research and Development from October 2017 to October 2020. | ||
Tyson Marshall Executive | General Counsel & Corporate Secretary | Tyson Marshall has served as General Counsel & Corporate Secretary at ATEC since July 2023 and previously held roles as Vice President, Associate General Counsel (2018-2023) and Director of Legal Affairs (2017-2018). He has also accumulated extensive legal experience at Mad Catz Interactive and in private legal practice. | ||
David Demski Board | Director at Alphatec Holdings, Inc. | Paragon 28, Inc.; VulcanForms, Inc. | David Demski has served as a director at ATEC since October 2023 and also advises Alphatec Spine, Inc. under a consulting agreement initiated in December 2024. He brings over 20 years of experience in the medical device industry, including previous executive roles at other companies. | |
David R. Pelizzon Board | Director | President and Member of the Managing Committee at Squadron Capital; Board Member at OrthoPediatrics | David R. Pelizzon has served as a director of ATEC since June 2020, contributing his extensive investment and financial expertise to the board. | |
Jeffrey P. Rydin Board | Director at ATEC | Director at DuraStat, LLC | Jeffrey P. Rydin has been serving as a director at ATEC since June 2017. He previously served as Special Advisor to the Board from September 2016 to June 2017 and brings over 30 years of experience in the medical device industry. | |
Karen K. McGinnis Board | Director | Board Member at Absci Corporation | Karen K. McGinnis has over 30 years of global financial and operational experience and has served as a Director at ATEC since June 2019, where she also chairs the Audit Committee and serves on the Compensation Committee. She has held key executive roles such as Chief Accounting Officer at Illumina, Inc. and has served on the boards of several companies, contributing extensive expertise. | |
Keith Valentine Board | Director | President, Chief Executive Officer, and Member of the Board of Directors at Intrinsic Therapeutics, Inc.; Chair of the Board at LocateBio Ltd.; Board Member at Regentis Biomaterials Ltd. | Keith Valentine has served as a director at ATEC since July 2024, following his previous role as Special Advisor to the Board since October 2023. He brings over 30 years of spine and orthopedics industry experience with executive and board roles at companies including NuVasive, Orthofix/SeaSpine, and Intrinsic Therapeutics, Inc.. | |
Mortimer Berkowitz III Board | Lead Director | Managing Partner of InnovaHealth Partners, LP since January 2017; Chairman of Blue Belt Holdings, Inc. since 2011; Chairman of BioHorizons, Inc. since 2006; Chairman of OrthoSpace since 2015; Chairman of Koelis, S.A. since 2019; Lead Director of Channel MedSystems, Inc. since 2021; Director of Radiaction Medical since January 2020; Director of Monteris Medical since 2022 | Mortimer Berkowitz III has served as a Director of ATEC since March 2005 and as Lead Director since October 2017. He brings extensive experience from investment banking and private equity, having held various leadership roles in healthcare-related companies. | |
Quentin Blackford Board | Director | CEO of iRhythm Technologies, Inc.; Director at Paragon 28, Inc. | Quentin Blackford is a seasoned finance executive with extensive experience in the healthcare industry. He has served as CEO of iRhythm Technologies, Inc. since October 2021 and as a director at ATEC since October 2017. | |
Ward W. Woods Board | Director | Chairman of the Advisory Board of the Stanford Woods Institute; Chair Emeritus and Life Trustee of the Wildlife Conservation Society; Member of the Council on Foreign Relations | Ward W. Woods has served as a director at ATEC since October 2017 and is currently the Chair of the Compensation Committee since at least Q1 2025. He brings extensive experience in finance, private equity, and corporate governance, having held several leadership roles across multiple organizations. |
- How do you plan to differentiate your unique corpectomy system—performed in the prone position—from competitor offerings, and what specific opportunities or challenges do you anticipate in driving adoption in trauma and tumor cases?
- With Q1 cash use hitting the low end of guidance despite transient working capital headwinds and elevated DSO levels, what concrete measures are being taken to ensure cash flow stability for the remainder of 2025?
- Can you provide detailed insights on how the recent sales force expansion, particularly among new versus tenured reps, is driving the 23% same-store growth, and what challenges remain in scaling a denser rep footprint across territories?
- Given the low single-digit tariff exposure on your EOS equipment—imported from France—how will these tariff costs be managed, and what strategies are in place to mitigate their impact on your cost of goods sold?
- With your robotic and navigation systems currently in the alpha phase and poised for an end-of-year launch, what specific workflow improvements and clinical outcomes are you targeting, and how soon do you expect these integrations to validate their impact in practice?
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
This competitor is identified as one of the most significant in the spinal implant industry, enjoying competitive advantages such as more established relationships with healthcare providers, broader product offerings, better name recognition, and greater resources for product research and development, clinical data, and regulatory clearances. | |
This competitor is highlighted as a major player in the spinal implant industry with substantial financial resources, entrenched relationships with physicians, and extensive experience in launching and marketing spinal implant products. | |
This competitor is noted for its significant financial resources, established distribution networks, and greater experience in developing and selling spinal implant products, posing strong competition in the market. | |
This competitor is recognized as a key competitor in the spinal implant industry, benefiting from substantial financial resources and a strong market presence. |
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
Integrity Implants Inc. and Fusion Robotics, LLC | 2023 | Deal Value & Structure: Alphatec Spine, Inc. paid $55.0 million in a cash transaction under an Asset Purchase Agreement, acquiring assets—including a navigation-enabled robotics platform—and treating the acquisition as a business combination with intangible assets and goodwill. Strategic Rationale: The deal supports integration and future R&D endeavors, with net proceeds from a related securities offering earmarked for various corporate purposes. |
EOS imaging | 2021 | Deal Value & Structure: Alphatec Holdings, Inc. acquired EOS imaging through a Tender Offer Agreement, with a total purchase price of approximately $116.9 million (cash consideration at specified per-share prices) and funding raised via a private placement. Strategic Rationale: The acquisition is aimed at integrating EOS’s low-dose 2D/3D imaging technology into spine surgery to enhance revenue growth and market expansion. |
Recent press releases and 8-K filings for ATEC.
- At its Annual Meeting on June 11, 2025, Alphatec Holdings, Inc. stockholders approved an amendment to the Certificate of Incorporation, increasing the total authorized shares of stock from 220,000,000 to 420,000,000, including common stock from 200,000,000 to 400,000,000. This amendment became effective on June 12, 2025.
- Stockholders also approved an amendment to the 2016 Equity Incentive Plan, increasing the number of shares available for issuance under the plan to 38,383,333 shares of Common Stock, effective June 11, 2025.
- Other approvals at the Annual Meeting included the election of nine directors and the non-binding advisory approval of named executive officer compensation.